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Abstract
Background:  Circulating levels of tumor necrosis factor (TNF) and lymphotoxin-α  (LT-α ) have
been associated with outcome in solid and hematologic malignancies. Within the TNF gene and the
LT-α  gene, polymorphisms have been identified at nucleotide positions -308 and +252, respectively.
The variant alleles for TNF are designated TNF1 and TNF2, the ones for LT-α  LT-α  (10.5 kb) and LT-
α  (5.5 kb). Of interest, TNF2 and LT-α  (5.5 kb) were shown to be associated with higher TNF and
LT-α  plasma levels than their counterparts. In the present study, we investigated the associations
of the above mentioned polymorphisms with risk of relapse in childhood acute lymphoblastic
leukemia (ALL) treated according to Berlin-Frankfurt-Münster (BFM) protocols.
Methods:  Matched case-control study of 64 relapsed and 64 successfully treated non-relapsed
childhood B-cell precursor ALL patients of standard and intermediate risk for treatment failure.
Results:  The odds ratio (OR) for the combined category of TNF1/TNF2 and TNF2/TNF2 genotypes
in comparison to the TNF1/TNF1 genotype was 1.17 (95 % confidence interval (CI) = 0.53 - 2.56, P
= 0.697). The ORs for the  LT-α  (10.5 kb/5.5 kb) and the LT-α  (5.5 kb/5.5 kb) genotypes with
reference to the LT-α  (10.5 kb/10.5 kb) genotype were 2.17 (95 % CI = 0.84 - 5.58, P = 0.107) and
0.5 (95 % CI = 0.09 - 2.66, P = 0.418), respectively.
Conclusions:  Our results do not suggest a major role of the investigated genetic polymorphisms
with regard to risk of relapse in standard- and intermediate-risk childhood B-cell precursor ALL
treated according to BFM protocols.
Background
Tumor necrosis factor (TNF) and lymphotoxin-α  (LT-α  ;
formerly TNF-β ) are cytokines with pleiotropic biologi-
cal activities including, for example, the induction of pro-
grammed cell death and the regulation of immune cell
proliferation and differentiation [1,2]. In a variety of
studies, plasma levels of TNF or LT-α  have been associ-
ated with outcome of certain autoimmune and infectious
diseases as well as solid and hematologic malignancies
[[3–6]]. Of interest, the secretion of TNF and LT-α  is be-
lieved to be influenced by genetic polymorphisms within
their genes located tandemly on the long arm of chromo-
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some 6 within the MHC class III region. One of the best
described of these polymorphisms is located at nucle-
otide position-308 within the TNF promoter region and
affects a consensus sequence for a binding site of the
transcription factor AP-2 [7,8]. Guanine at position-308
defines the common TNF1 allele and adenine the less
common TNF2 allele. With regard to the LT-α  gene, a
polymorphism at nucleotide position 252 within the first
intron was reported to influence LT-α  plasma levels. This
single nucleotide polymorphism (A252G) affects a phor-
bol ester-responsive element and distinguishes two alle-
les that have been designated LT-α  (10.5 kb) and LT-α
(5.5 kb) [9]. Both the TNF2 and the LT-α  (5.5 kb) allele
have been shown to correlate with elevated TNF or LT-α
plasma levels. Besides a more severe outcome of autoim-
mune or infectious diseases and of particular interest to
us, the TNF2 and the LT-α  (5.5 kb) alleles have been as-
sociated with an adverse outcome in lymphoid malig-
nancies [[10–15]].
In the present study, we genotyped a matched case-con-
trol study group of 64 relapsed and 64 non-relapsed pa-
tients with childhood acute lymphoblastic leukemia
(ALL) for the above described genetic polymorphisms
within the TNF and LT-α  genes in order to assess their
predictive potential with regard to relapse in childhood
ALL.
Table 1: Characteristics of 64 relapsed case subjects and 64 successfully treated matched control subjects with acute lymphoblastic 
leukemia selected from trials ALL-BFM 86 and ALL-BFM 90
Cases (%) Controls (%)
Trial
ALL-BFM 86 35 (54.7) 35 (54.7)
ALL-BFM 90 29 (45.3) 29 (45.3)
Sex
Male 42 (65.6) 42 (65.6)
Female 22 (34.4) 22 (34.4)
Age (y)
<1 1 (1.6) 1 (1.6)
1-9 56 (87.5) 56 (87.5)
10-14 6 (9.4) 7 (10.9)
15-18 1 (1.6) -
WBCa (103/µ l)
<10 42 (65.6) 41 (64.1)
10-<50 21 (32.8) 22 (34.4)
≥  50 1 (1.6) 1 (1.6)
Immunophenotype
c-ALLb 54 (84.4) 54 (84.4)
pre-B-ALLc 10 (15.6) 10 (15.6)
Risk groupd
standard 23 (35.9) 23 (35.9)
intermediate 41 (64.1) 41 (64.1)
high - -
DNA indexe
<1.16 30 (46.9) 30 (46.9)
≥  1.16 12 (18.8) 7 (10.9)
not examined 22 (34.4) 27 (42.2)
Genotype
normal 4 (6.3) 10 (15.6)
11q23 abberations - 1 (1.6)
t(1;19) 1 (1.6) -
t(9;22) - -
other 15 (23.3) 13 (20.3)
not examined 44 (68.8) 40 (62.5)
a white blood cell count b common acute lymphoblastic leukemia c precursor B-cell acute lymphoblastic leukemia d therapy stratification in risk groups 
was mainly based on initial leukemic cell mass estimate and initial treatment response [16–18]e ratio of DNA content of leukemic G0/G1 cells to 
normal diploid lymphocytesBMC Blood Disorders (2001) 1:2 http://www.biomedcentral.com/1471-2326/1/2
Methods
Patients and study design
The present study utilizes patients and data from the
ALL-BFM 86 and ALL-BFM 90 multicenter trials of
childhood ALL, conducted by the BFM study group. De-
sign, conduct, analysis, and results of the ALL-BFM 86
and ALL-BFM 90 trials are described in detail elsewhere
[16,17]. In both trials treatment was stratified into three
branches (standard, intermediate, and high risk), mainly
according to the leukemic cell mass estimate and treat-
ment response. Treatment (in most cases induction, con-
solidation, reinduction, maintenance) consisted of
intensive multiagent chemotherapy regimens employing
standard drugs (e.g. prednisone, vincristin, daunoru-
bicin, L-asparaginase, cyclophosphamide, cytarabine, 6-
mercaptopurine, 6-thioguanin, methotrexate). Parts of
the study group received cranial radiotherapy.
The establishment of the present case-control study
group has been described previously [18]. Briefly, re-
lapsed patients from ALL-BFM 86 and ALL-BFM 90
with an available remission peripheral blood or bone
marrow smear were included as cases into the study
group if they could be matched to a successfully treated
patient with an available remission peripheral blood or
bone marrow smear (control individual) according to the
following criteria: sex, age at diagnosis (±  6 months),
white blood cell count (WBC) at diagnosis (±  10,000/µ l),
immunophenotype, trial, risk group, and treatment arm
within the risk group of the respective trial. The latter
criterion assured similarity of treatment between cases
and controls. Controls had to have a minimum follow-up
of 5 years. In case of relapses occurring later than 5 years
of diagnosis, the follow-up for the control subject had to
be at least as long as the time from date of initial diagno-
sis to date of relapse diagnosis in the case subject. If more
than one control subject was available, the subject with
the closest initial WBC at diagnosis with reference to the
case subject was chosen. All spare remission peripheral
blood or bone marrow smears were derived from official
routine remission control examinations at time points
during the first 6 month of treatment according to the
study protocols of ALL-BFM 86 and 90.
Genotype analysis
Genomic DNA was isolated from remission bone marrow
or peripheral blood smears as described before [18].
Genotypes for TNF and LT-α  were determined by
polymerase chain reaction (PCR)-based restriction frag-
ment length polymorphism (RFLP) analysis. The -308
TNF promoter polymorphism was analyzed by incorpo-
rating it into an Ncol restriction site that was created by
introducing a single base change within the forward
primer [7]. Primer sequences were: forward 5'-AG-
GCAATAGGTTTTGAGGGCCAT-3'; reverse 5'-TCCTC-
CCTGCTCCGATTCCG-3'. The LT-α  polymorphism at
nucleotide position +252 was analyzed by PCR amplifi-
cation of a 368 bp fragment using the following primer
pair: forward 5'-CTCCTGCACCTGCTGCCTGGATC-3';
reverse 5'-GAAGAGACGTTCAGGTGGTGTCAT-3' [10].
The amplified PCR products were digested overnight
with Ncol and analyzed on 3.0 % Nusieve (TNF) or 3.0 %
conventional agarose gels (LT-α ). In case of presence of
the TNF1 allele, the amplified 107 bp fragment from the
TNF promoter is cut into two fragments of 87 and 20 bp,
a fragment amplified from TNF2 remains uncut [7]. The
368 bp fragment from LT-α  is unaffected by Ncol diges-
tion in case of presence of a LT-α  (10.5 kb) allele while a
PCR product amplified from a LT-α  (5.5 kb) allele is cut
into two fragments of 133 and 235 bp [10].
Table 2: Distribution of tumor necrosis factor (TNF) and lymphotoxin-α  (LT-α ) genotypes and their association with the occurrence of 
relapse in 64 case subjects and 64 successfully treated matched control subjects with acute lymphoblastic leukemia from ALL-BFM trials 
86 and 90
Cases (%) Controls (%) ORa (95 % CIb) P value
TNF
TNF1/TNF1 41 (64.1) 43 (67.2) 1.00
TNF1/TNF2 21 (32.8) 20 (31.3) 1.17c (0.53-2.56) 0.697
TNF2/TNF2 2 (3.1) 1 (1.6)
LT-α
10.5 kb/10.5 kb 25 (39.1) 30 (46.9) 1.00
10.5 kb/5.5 kb 32 (50.0) 23 (35.9) 2.17 d (0.84-5.58) 0.107
5.5 kb/5.5 kb 7 (10.9) 11 (17.2) 0.50 d (0.09-2.66) 0.418
a odds ratio b confidence interval c odds ratio for the combined category of TNF1/TNF2 and TNF2/TNF2 genotypes d odds ratio for the combined 
category of LT-α  (10.5 kb/5.5 kb) and LT-α  (5.5 kb/5.5 kb) with reference to LT-α  (10.5 kb/10.5 kb) was 1.5 (95% CI = 0.68-3.32; P = 0.317)BMC Blood Disorders (2001) 1:2 http://www.biomedcentral.com/1471-2326/1/2
Statistical analysis
After frequencies were calculated for descriptive purpos-
es, correlation analyses (contigency coefficients for nom-
inal data, Spearman correlation coefficients for ordinal
data, Pearson correlation coefficients for continous data)
were computed to investigate the interrelationships be-
tween TNF genotype, LT-α  genotype and important clin-
ical prognostic variables such as sex, age at diagnosis,
WBC at diagnosis, and immunophenotype. Differences
in the distribution of categorical variables were analyzed
by Χ 2 or Fisher's exact test. The association between TNF
and LT-α  genotypes and relapse of leukemia was exam-
ined by use of conditional logistic regression analysis to
calculate odds ratios and their 95 % confidence intervals.
Genotypes and genotype combinations were used as cat-
egorical variables in the analyses. The association of gen-
otypes with time to relapse was analyzed by log rank
tests. Computations were peformed using SAS software
(SAS-PC Version 6.04, SAS Institute Inc., Cary, NC).
Results and Discussion
Table 1 shows the distribution of matching variables and
genetic analyses (DNA index and karyotype) in the 64 re-
lapsed case subjects and the 64 successfully treated con-
trol subjects as previously described [18]. Within our
entire study population of 128 patients, 84 (65.6%) pa-
tients were homozygous for the TNF1 allele, 41 (32.0%)
patients were heterozygous (TNF1/TNF2) and 3 (2.3%)
patients were homozygous for the TNF2 allele. With re-
gard to LT-α , we observed 55 (43.0%) patients being ho-
mozygous for the LT-α  (l0.5 kb) allele and 55 (43.0%)
patients being heterozygous (LT-α  (10.5 kb)/ LT-α  (5.5
kb)). Eighteen (14.1%) patients were homozygous for the
LT-α  (5.5 kb) allele. The prevalences observed in our
study are similar to the ones reported by Demeter et al.
in a healthy German control sample [15]. Thus, it seems
unlikely that TNF or LT-α  genotypes are associated with
the pathogenesis of childhood B-cell precursor ALL in
the German population. With regard to clinically impor-
tant variables, no particular associations between the
TNF and LT-α  genotypes and sex, age at diagnosis, WBC
at diagnosis, immunophenotype, and risk group were
observed (data not shown). Table 2 shows the prevalenc-
es of the investigated TNF and LT-α  genotypes by case-
control status of our study subjects. In addition, Table 2
contains information on the association of the -308 TNF
promoter polymorphism and the intronic LT-α  polymor-
phism at nucleotide position 252 with risk of ALL relapse
in our study subjects. For both genotypes, no particular
associations with risk of ALL relapse were observed (Ta-
ble 2). As reported in previous studies, the TNF1 allele
was significantly linked to the LT-α  (l0.5 kb) allele as was
the TNF2 allele to the LT-α  (5.5 kb) allele (Χ 2 test; P <
0.01) [10,13]. The strong association between polymor-
phic  TNF and LT-α  alleles made Warzocha and col-
leagues to use haplotypes for their outcome analysis in a
study on lymphoma outcome related to TNF and LT-α  al-
leles [10]. In their study, the authors found that the pres-
ence of at least two TNF or LT-α  high-producer alleles
(TNF2 or LT-α  (5.5 kb)) was an independent risk factor
for progression-free survival in adult diffuse large-cell
lymphoma patients [10]. When we analyzed the risk of
relapse conferred by so-called high-producer TNF/LT-α
haplotypes (at least two high-producer alleles) in com-
parison to low-producer TNF/LT-α  haplotypes (less
than two high-producer alleles) we also failed to observe
any meaningful association in our study population
(odds ratio (OR) = 1.08; 95% confidence interval (CI) =
0.51 - 2.30; P = 0.841). However, based on the discordant
pairs observed in our study, we only had a power of 80%
to detect risks greater than 3.0 conferred by the TNF1/
TNF2 and the LT-α  (10.5 kb)/LT-α  (5.5 kb) genotypes or
by the high-producer TNF/LT-α  haplotypes. Therefore,
we neither can exclude smaller effects on treatment out-
come mediated by the above mentioned exposures nor
reasonably exclude clinically important effects of the
rare TNF2/TNF2 or the LT-α  (5.5 kb)/ LT-α  (5.5 kb) gen-
otype. Furthermore, we investigated possible influences
of the analyzed TNF and LT-α  genotypes on time to re-
lapse or on site of ALL relapse (isolated bone marrow re-
lapse; combined and isolated CNS relapse; combined
and isolated testis relapse) and, as above, did not detect
any associations.
From the data presented in this study, we are not able to
generalize our findings to childhood ALL patients of all
immunophenotypic subgroups since we only investigat-
ed common and pre-B-cell ALLs. Similarly, we were not
able to assess an association of the investigated TNF and
LT-α  genotypes on risk of relapse in high-risk childhood
ALL patients since also these patients were not part of
our study group. The latter point may be interesting to
pursue as Demeter and colleagues, in a study on TNF and
LT-α  polymorphisms in chronic lymphocytic leukemia
(CLL), detected an increase of the LT-α  (10.5 kb) allele at
more advanced disease stages [15]. Thus, additional in-
vestigations including childhood ALL patients of all clin-
ically relevant subgroups are needed to lead to more
conclusive results. However, for the subgroup of child-
hood B-cell precursor ALL of standard and intermediate
risk treated according to BFM regimens that was ana-
lyzed in the present study, the investigated genetic TNF
and LT-α  polymorphisms do not seem to play a major
role with regard to risk of relapse.
Conclusions
In a matched case-control group of 64 relapsed and 64
successfully treated childhood B-cell precursor ALL pa-
tients (all at standard or intermediate risk), the TNF
gene polymorphism at nucleotide position -308 and theBMC Blood Disorders (2001) 1:2 http://www.biomedcentral.com/1471-2326/1/2
LT-α  gene polymorphism at nucleotide position +252
were not significantly related with risk of ALL relapse.
Our results do not suggest a major role of the investigat-
ed genetic polymorphisms with regard to risk of relapse
in childhood B-cell precursor ALL of standard and inter-
mediate risk treated according to BFM protocols.
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